This site and its contents are intended to assist current and potential investors in making investment decisions. Small Pharma is a research and development company with currently no approved medicines. Therefore, the information provided on this site is not intended for healthcare professionals, patients, or members of the public.

 

Everyone deserves the option of better mental health

Small Pharma is a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Corporate Presentation

Everyone deserves the option of better mental health

Small Pharma is a biotechnology company researching and developing short-acting psychedelics with therapy for under-served mental health conditions.

Corporate Presentation

Today’s antidepressants leave a third of patients behind. This mental health epidemic needs solutions, not wishful thinking.

Peter Rands

Co-Founder, Small Pharma

We’re on a mission to fast track the development of short-acting psychedelic therapies for patients affected by depression and other mental health conditions .

We believe people deserve treatments that work quickly, have long lasting benefits and are well tolerated. So we're taking a radically different approach.

Carol, Chief Scientific and Medical Officer
Play Video about Carol, Chief Scientific and Medical Officer

Who we are,
what we do

Find out more about our story and meet the team behind Small Pharma

‘We do have to start looking for a completely different approach, and try something completely out of the box.’

Dr Carol Routledge, CMSO

It has been a real pleasure working with Small Pharma since the launch of Drug Science’s Medical Psychedelics Working Group in July 2020. Small Pharma have been a partner since the beginning, together we have achieved much and have far-reaching plans for the future.
Prof Jo Neill
Scientific Committee at Drug Science
Traditional talk therapy can be extremely expensive and for some it takes years to process their psychological issues. Often it is those rare experiential moments when a re-enactment of old wounds surfaces that provide a real shift in the therapeutic process. Psychedelics can provide those experiential moments and thus hold great potential in catalysing therapy.
Michelle Baker Jones
Study Therapist on Small Pharma's clinical trial
Small Pharma’s endeavour to test psychedelic therapy for depression is not only interesting and timely but also very important. Their ambitious research program has the potential to make a positive difference for patients suffering depression.
Dr David Erritzoe
Clinical Director at the Centre for Psychedelic Research

Chief Executive Officer

Chief Medical & Scientific Officer

Chief Operating Officer

Chief Innovation & IP Officer

Chief Manufacturing & Development Officer

Chief Financial Officer

Our approach

A novel approach to drug development, by innovating on known compounds to create new and protectable mental health treatments.

Our goal is to develop treatments that provide fast-acting relief, with long-lasting effects, that are scalable in-clinic treatments.

Our goal is to develop treatments that:


  provide fast-acting relief

  provide long-lasting effects

  are scalable in-clinic

 

Our Approach

 

Accelerated drug development

We innovate on known compounds. This allows us to accelerate and reduce the risk of early drug development to ultimately speed up progress to trial potential medicines in human clinical trials.

Scalability

We focus on progressing therapies that have the potential to become scalable treatments in critical areas of unmet need, such as depression.

Fast-acting, long-lasting

Our goal is to develop optimized therapies for patients that target better outcomes than current treatments on offer, with rapid and durable relief.

Robust IP protection

We have a robust and multi-layered IP program to protect our innovation.

Our focus is short-acting psychedelics

Psychedelics with supportive therapy may have potential as antidepressant treatments.

Research to date has shown great potential with psychedelics in treating mental health conditions. Psychedelic compounds vary in their duration of subjective effects, often referred to as 'the psychedelic experience', which can range from minutes to more than 12 hours. We want to create scalable in-clinic mental health treatments, so we're focused on short-acting psychedelics with supportive therapy.

Research & trials

molecule

Years of R&D development

Medicines in development

Active clinical trials

Investor News

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates


    Corporate Presentation

    Follow us: